

RESEARCH

Open Access

Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy

Chao Wu¹, Yong Liu², Qi Zhao¹, Guangmei Chen¹, Junhao Chen², Xiaomin Yan², Yi-Hua Zhou^{1,2}, Zuhu Huang^{3*}

Abstract

Background: We aimed to clarify whether soluble CD40 ligand (sCD40L) activated B cells may be loaded with HBcAg18-27 peptide and served as antigen-producing cells (APCs) to induce HBV-specific cytolytic T lymphocytes (CTLs).

Results: Human B cells could be cultured in the presence of sCD40L up to 54 days, and the proportion of B cells in the S phase increased from 0% to 8.34% in the culture. The expression of CD80, CD86, major histocompatibility complex (MHC) classes I and II molecules on the sCD40L-activated B cell was significantly increased after long-time culture. Cytometry and fluorescence microscopy showed that more than 98% sCD40L-activated B cells were loaded by the HBcAg peptide. Furthermore, the peptide-pulsed activated B cells could induce HBcAg18-27 specific CTLs.

Conclusions: Our results demonstrate that sCD40L-activated B cells may function as APCs and induce HBV-specific CTLs.

Background

Efficient antigen presentation by antigen presenting cells (APCs) is critical for inducing T-cell mediated immunity *in vivo* [1,2]. Dendritic cells (DCs), activated macrophages, and activated B cells are all capable of presenting antigen peptides. DCs are considered to be highly efficient at antigen capture, processing, and migration [3]. Therefore, DCs have been used to generate antigen-specific T cells for immunotherapy [4-6].

Recently, it has been demonstrated that B cells may function as APCs [1,7] in addition to the essential role in the humoral immune response. Banchereau *et al* first reported the "CD40 system" [8], and suggested to use CD40 ligand (CD40L) stimulated B cells as an alternative or complementary APC. The CD40L-activated B cells may be continually expanded and the B cells significantly up-regulate the expression of major histocompatibility complex (MHC) class I and class II and induce

the expression of CD80 and CD86. Antigen-specific CD40L-activated B cells may efficiently endocytose and present antigens, such as protein, RNA, and cDNA, to prime primary T cells and boost robust memory T-cell responses [9]. More importantly, activated B cells may also prime naive T-cell responses against neoantigens *ex vivo* as DCs do [9]. Thus, the activated B cells may serve as cellular adjuvants to present antigens *in vivo* [10].

The mechanism of chronic hepatitis B virus (HBV) infection remains unclear. Previous studies have suggested that functional impairment of DCs may mediate suppression of viral-specific T-cell immune response, resulting in viral persistence in the chronic HBV infection [11-13]. As another type of important APCs, B cells may also function as primary APC in CHB infection [14]. However, little is known whether CD40L-activated B cells may present HBV antigen to T cells.

In this study, we set up an effective culture method for long-term maintenance of B cells *in vitro*, in which the B cells are activated by human soluble CD40L (sCD40L). Furthermore, we provide evidence that the

* Correspondence: wuchao62@yahoo.com.cn

³Department of Infectious Diseases, First Affiliated Hospital, Nanjing Medical University, Nanjing, PR China

Full list of author information is available at the end of the article

activated B cells may serve as APCs to present core peptide of HBV to cytolytic T lymphocytes (CTLs).


Results

Proliferation of B cells activated by sCD40L

As a terminal cell type, B cells in peripheral blood mononuclear cells (PBMCs) can usually be cultured for 2-3 weeks only, which limits the application of B cells as APCs. To prolong the culture period, we added sCD40L into the culture of PBMCs, which resulted in the prolonged culture period as long as 54 days in the presence of sCD40L. FACS analyses showed that the percentage of B cells in the culture increased significantly over the time, and B cells accounted for about 80% of the total PBMCs when the cells were cultured for 54 days (Figure

1a and 1b). In contrast, the PBMCs cultured in the absence of sCD40L contained no B cells analyzed by cytometry 20 days after culture (Figure 1d).

Additionally, cell cycle profiles analyzed by cell cycle distribution indicated that the G1 phase decreased from 99.87% on day 3 to 88.92% on day 45, concomitant with an increase in cells in the S phase from 0% to 8.34% and the G2/M phase from 0.13% to 2.74% (Figure 1c). However, no decrease in the sub-G1 cells was detected in the culture without sCD40L. The results demonstrated that the B cells were able to re-enter the S phase and proliferate in the presence of sCD40L compared with the cells cultured in the absence of sCD40L. Total number of B cells in the presence of sCD40L increased from 8.84×10^5 to 8.61×10^6 , while the number of B



cells in the absence of sCD40L was decreased (Figure 1d). Taken together, in accordance with the previous reports [15], our data demonstrated that B cells may proliferate for significantly long period of time in the presence of sCD40L. After completion of the experiments on the above donor, we repeated all the culture process from another donor's sample; the results were comparable or almost same.

Increased expression of CD80, CD86, MHC classes I and II on cell surface of sCD40L-activated B cells

Previous studies demonstrate that human B cells isolated from peripheral blood may be activated and the expression levels of CD80, CD86, MHC classes I and II molecules on the cell surface is efficiently up-regulated by infection with Epstein-Barr virus or co-culture with mitogen-induced cells transfected with the human CD40L [16,17], and the B cells may serve as APCs and induce specific CTLs. However, the previous culture systems introduced the extraneous source germ cells or virus and limited the further clinical application researches. In our experiment, we cultured B cells with recombinant human (rh) sCD40L and the cells could be continuously expanded in long term culture. To investigate whether the activated B cells may serve as APC, we detected the expression of costimulatory molecules, including CD80, CD86, MHC classes I and II on the cell surface by flow cytometry. Figure 2 presents that the levels of these molecules on the sCD40L-activated B cells were significantly increased. In contrast, the levels of all above cell surface molecules were very low on the B cells before activation. Thus, the results suggest that the B cells activated by sCD40L may have the function of APCs.

Visualization of antigen delivery to sCD40L-activated B cells

Since the expression levels of CD80, CD86, MHC classes I and II molecules on the B cell surface were significantly increased after long-time culture with sCD40L, sCD40L-activated B cells may have the function of antigen presentation. To clarify whether this is true or not, we cultured the cells in the presence of a fluorochrome-labeled peptide, which was derived from the core protein of HBV. Cytometry analysis showed that more than 98% of sCD40L-activated B cells had the green fluorescence (Figure 3a), indicating that there was HBV core peptide in the cells or on the surface of the cells and the B cells might be loaded by the HBV core peptide. We further observed the cells under fluorescence microscope and found that the red fluorescence located at B cell surface was CD19-PE and the green fluorescence (superimposition of the green FITC fluorescence and the red CD19-PE becomes yellow) located

in cytoplasm was HBV core peptide. The activated B cells showed strong fluorescence after peptide pulsing at concentrations even lower than 25 $\mu\text{g}/\text{mL}$ (Figure 3b). All of the above results indicate that the sCD40L-activated B cells may be loaded with the HBV core peptide.

The result of the HBcAg18-27 specific CTLs

To investigate whether the sCD40L-activated B cells may present the HBV core peptide to T cells and induce specific cytotoxic T cell responses, we co-cultured the autologous T cells and sCD40L-activated B cells loaded by HBV core peptide, and then detected the CTL responses against peptides of HBcAg 18-27 by pentamer analysis. FCM analyses showed that 0.248% of the T cells were induced to be HBcAg18-27 specific CTLs, while such CTLs were only 0.122% in the absence of activated B cells (Figure 4). Hence, the sCD40L-activated B cells may function as APCs and induce HBV-specific CTL.

Discussion

Recently, DC-based immunotherapy has gained a lot of interest in clinical immunology [18]. The high efficiency of DC vaccines has been proved in anti-tumor and anti-virus immunological treatment. However, the DCs constitute only 0.1-0.5% of human PBMC. Technical difficulty and high cost to obtain sufficient number of highly enriched mature DCs have limited the clinical applications of dendritic cell vaccine.

In this study, we used recombinant human GMP-quality trimeric soluble CD40L to activate PBMC-derived B cells. We established and optimized the culture system for CD40L-B cells, which allows B cell activation and proliferation without the contamination from extraneous source germ cells and genes. It was noted that rh sCD40L-activated B cells could be cultured *in vitro* for up to 54 days under the culture condition. At the same time, B cells significantly up-regulated MHC class I and class II expression and induced expression of CD80 and CD86 after activated by rh sCD40L. Unlike some recent studies, in which B cells were co-cultured with NIH3T3 cells or other tumor cells which steadily express CD40L [8,19], our results demonstrated that B cells could be activated and expanded for prolonged period of time. While previous culture system has introduced the extraneous source germ cells and has limited the further clinical application researches, the accomplishment of present work may be taken as an alternative way to activate primary human B cells *in vitro*.

Because sufficient expression of MHC and costimulatory molecules is closely associated with APC function, phenotypic analysis of the cell surface molecules is applied as a reliable surrogate readout for APC function of B cells [20]. Moreover, costimulatory molecules CD80 and CD86 expressed on APCs are required for the





Figure 2 Detection of the expression of CD80, CD86, and MHC I and II on sCD40L-activated human B cells as surrogates of APC. (a) The expression of surface molecules MHC-I, MHC-II, CD80, and CD86 on B cells were examined by gating CD19 positive cells by FACS analysis. (b) The expression of MHC-I and MHC-II on B cells was expressed as the mean fluorescence intensity. (c) The expression of CD80 and CD86 on B cells was expressed as the percents in all B cells.

development of T cell responses, which play important roles in the differentiation of Th1- or Th2-phenotypes [21]. CD80 and CD86 expressed on the surface of antigen-presenting cells interact with CD28 and cytotoxic T lymphocyte antigen-4 expressed on activated T cells. Interaction between CD80/86 and CD28 mediates critical T cell stimulatory signals, which may cause T cells to stably secrete IL-2 and other cytokines, and maintain T cell survival [22]. Our experiments demonstrate that the rh sCD40L may activate the B cells from PBMCs, and induce a strong up-regulation of those surface molecules associated with antigen processing on human B lymphocytes. Functionally, our study has moved a step forward to demonstrate that 98% of sCD40L-activated B cells may be loaded with HBcAg18-27 peptide.

Furthermore, after co-cultured with the peptide-pulsed CD40L-B cells, more HBcAg18-27 specific CTLs were detected in autologous PBMCs. All of these results indicate that the CD40L-B cells have the characteristics of APCs.

The weakness of this study is that all data were just derived from 2 healthy donor samples. However, we performed the experiments separately, not at the same time, i.e., we cultured the B cells from one donor and did the relevant experiments, and then we repeated all the experiments using another donor's sample, the results were comparable or almost same. Thus, we consider that the long-term culture system for B cells developed in this work is reproducible and the data in the present work are sufficient to support our conclusion.




Conclusions

In summary, the present study has established an approach for a long term culture of human B cells from PBMCs under the stimulation of sCD40L and the sCD40L activated B cells may serve as APCs. Furthermore, antigen presenting activity of sCD40L-activated B cells was evidenced by antigen-loading and the induction of HBcAg18-27 specific CTLs in autologous PBMCs. Thus, CD40L-activated B cells may be used as a potential source of APCs for adoptive immunotherapy for chronic HBV infection.

Methods

Blood samples

Peripheral blood (30 ml) was obtained by venipuncture from two healthy donors with HLA-A2+. The donors



gave the consent and all the experiments were approved by the Ethics Committee of Nanjing Drum Tower Hospital, Nanjing University Medical School, in accordance with guidelines of the Nation Health and Medical Research Council of China. PBMCs were isolated by Ficoll-density centrifugation, rinsed twice with iscoves modified Dulbecco medium (IMDM) (Gibco BRL, Carlsbad, USA). Approximately 3×10^7 PBMCs were acquired; 1.6×10^7 PBMCs were further cultured for preparing activated B cells by sCD40L, and the surplus cells were kept in cryopreservation fluid and frozen in liquid nitrogen for pentamer analysis.

Activation of B cells by sCD40L

PBMCs were plated in wells of 6-well plates (8×10^6 cells in 4 ml per well) in IMDM supplemented with 10% human serum with blood type AB, rh IL-4 (2 ng/ml) (R&D Systems, Minneapolis, USA), insulin (5 μ g/ml) (Roche, Mannheim, Germany), cyclosporin A (CsA) (5.5×10^{-7} M) (Novartis, Basel, Switzerland), transferrin (50 μ g/ml) (Eappel, USA), and gentamicin (15 μ g/ml) (Lukang, Shandong, China). Good medical practice (GMP)-quality trimeric rh soluble CD40L (rh sCD40L) (R&D Systems, Minneapolis, USA) was added to a final concentration of 2 μ g/ml. The culture was maintained by replacing half medium with the same medium, in which CsA and sCD40L were freshly added. B cells that were cultured in the same medium except that sCD40L were omitted served as controls.

Cell proliferation assay

Cell proliferation was determined by analysis of cell cycle distribution with flow cytometry using Cycle Test Plus DNA Reagent kit (Becton Dickinson, San Jose, USA) as previously described [23]. In brief, the cultured cells (1×10^5) were collected and digested by trypsin, followed by adding trypsin inhibitor and RNAase, then mixed with propidium iodide in the dark condition at 4 $^{\circ}$ C. The cells were then subjected to run on the BD FACSCanto flow cytometer (BD Biosciences, CA, USA). Based on the intensity of the fluorescent light signal emitted by the DNA-binding dye, the cell populations were located in four distinct phases, which may be recognized in static phase (G0/G1), DNA synthesis phase (S), and DNA mitosis phase (M), respectively [23].

Assay for cell surface molecules

The cell surface molecules, including CD86, CD80, MHC classes I and II, on sCD40L-activated B cells were analyzed by flow cytometry. In brief, 1×10^6 PBMCs in 100 μ l PBS were rinsed twice with PBS containing 2% FBS and divided into 3 tubes: anti-CD19-APC, anti-CD86-FITC, and anti-CD80-PE were added into the first tube, anti-CD19-APC, anti-MHC-II-FITC and

anti-MHC-I-PE were added into the second tube, and in the third tube, negative isotype control staining reactions were in parallel performed with a saturating concentration of irrelevant mouse IgG1-FITC and IgG1-PE. All above seven antibodies were purchased from BD Biosciences (BD PharMingen, San Diego, CA). After incubated for 20 min and rinsed with PBS, the cells were fixed with 1% paraformaldehyde in PBS. FACS analysis was performed on the BD FACSCanto flow cytometer. B cells were gated on CD19-positive cells for analyzing the cell surface molecules.

Analysis of peptide pulsing

HBV derived peptides were used for peptide pulsing study as previously described [24,25] with modifications. The HLA-A*0201-binding peptide of HBV core 18-27 (HBcAg 18-27, Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val, FLPSPDFPSV), a confirmed HLA-A 2.1-restricted CTL epitope and derived from the HBV core protein [26], was obtained from Sangon (Shanghai, China). For the MHC class I experiments, the peptide was conjugated by FITC at the first residue of the N-terminus. CD40L-activated B cells were harvested from culture, washed 3 times, and resuspended in serum-free IMDM at 2×10^5 cells/ml and seeded into 24-well plates (1 ml/well). After incubation with the FITC-conjugated peptide for 12-18 hours, the cells were harvested, washed, and resuspended in PBS. Fluorescence analysis was performed immediately on the BD FACSCanto flow cytometer for detecting the ratio of B cells specific binding of HBV core peptide. The residual cells were observed by fluorescence microscope (Zeiss, Goettingen, Germany) for determining the location of HBV core peptide in B cells. B cells were also incubated with no FITC-conjugated peptide under the same condition for pentamer analysis.

Pentamer analysis

On day 45 of B cells culture from one donor, the CD40L-activated B cells were used as the source of APCs for stimulation of autologous T cells. In brief, the frozen PBMCs were rapidly thawed in a 37°C water bath and then cultured at a concentration of 2×10^6 cells/ml in RPMI 1640 supplemented with 10% fetal bovine serum and rhIL-2 (10 ng/ml) (R&D Systems). On day 4, the cultures were replaced with the same medium, followed by co-culture with the peptide-pulsed CD40L-activated B cells. After 4 days, the cells were harvested, washed, and mixed with both anti-CD8-FITC and PE-labeled HLA-A2 pentamer complexes against the HBV core 18-27 peptide (ProImmune, Oxford, UK). The cells were resuspended in 500 µl of PBS and two-colour analysis was performed by BD FACSCanto flow cytometer. For each analysis, 100 000 events were acquired. PBMCs

that were cultured in the same medium omitted peptide-pulsed CD40-B served as controls.

Acknowledgements

This work was supported by grants from National Natural Science Foundation of China (No. 30872234) and grants from Ministry of Public Health of the People's Republic of China, MOPH (No. WKJ2006-2-9).

Author details

¹Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, PR China.

²Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, 321 Zhongshan Road, Nanjing, Jiangsu, PR China.

³Department of Infectious Diseases, First Affiliated Hospital, Nanjing Medical University, Nanjing, PR China.

Authors' contributions

CW performed the experiments, analyzed the data, and drafted the manuscript. YL, QZ and GC performed the experiments and analyzed the data. XY and JC collected the samples and assisted in the performance of the experiments. YHZ interpreted the data and revised the manuscript. ZH designed the study, interpreted the data and critically revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 13 October 2010 Accepted: 23 December 2010

Published: 23 December 2010

References

1. Steinman RM: The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol* 1991, **9**:271-296.
2. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. *Nature* 1998, **392**:245-252.
3. Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. *Curr Opin Immunol* 1997, **9**:10-16.
4. Chang JW, Hsieh JJ, Shen YC, Ho E, Chuang CK, Chen YR, Liao SK, Chen JS, Leong SP, Hou MM, Chang NJ, Wang CH: Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. *Melanoma Res* 2009, **19**:309-315.
5. Cao DY, Yang JY, Yue SQ, Tao KS, Song ZS, Wang DS, Yang YL, Dou KF: Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. *Cell Immunol* 2009, **259**:13-20.
6. Chen W, Zhang Z, Shi M, Chen L, Fu J, Shi F, Zhang B, Zhang H, Jin L, Wang FS: Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. *Clin Immunol* 2008, **129**:295-303.
7. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. *Blood* 2004, **103**:2046-2054.
8. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM: CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. *J Clin Invest* 1997, **100**:2757-2765.
9. Coughlin CM, Vonderheide RH: Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality. *Cancer Biol Ther* 2003, **2**:466-470.
10. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto M, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. *J Immunol* 2002, **169**:2164-2171.

11. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J, Janssen HL: **Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.** *Hepatology* 2004, **40**:738-746.
12. Beckebaum S, Cicinnati VR, Dworacki G, Müller-Berghaus J, Stolz D, Hamaha J, Whiteside TL, Thomson AW, Lu L, Fung JJ, Bonham CA: **Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection.** *Clin Immunol* 2002, **104**:138-150.
13. Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, Broelsch CE, Gerken G: **Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type I response in vitro: mechanisms for viral immune escape.** *Immunology* 2003, **109**:487-495.
14. Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL: **Role of B cells in antigen presentation of the hepatitis B core.** *Proc Natl Acad Sci USA* 1997, **94**:14648-14653.
15. Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrach MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS: **CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.** *Clin Exp Immunol* 2009, **155**:249-256.
16. Zhu F, Ramadan G, Davies B, Margolis DA, Keever-Taylor CA: **Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.** *Clin Exp Immunol* 2008, **151**:284-296.
17. Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S: **B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.** *Cytotherapy* 2005, **7**:62-73.
18. Akbar SM, Horiike N, Onji M: **Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection.** *World J Gastroenterol* 2006, **12**:2876-2883.
19. Yoon SH, Cho HI, Kim TG: **Activation of B cells using Schneider 2 cells expressing CD40L for the enhancement of antigen presentation in vitro.** *Exp Mol Med* 2005, **37**:567-574.
20. Noorchashm H, Reed AJ, Rostami SY, Mozaffari R, Zekavat G, Koeberlein B, Caton AJ, Naji A: **B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection.** *J Immunol* 2006, **177**:7715-7722.
21. Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B: **Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.** *J Immunol* 1999, **162**:5576-5583.
22. Salomon B, Bluestone JA: **Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.** *Annu Rev Immunol* 2001, **19**:225-252.
23. Nunez R: **DNA measurement and cell cycle analysis by flow cytometry.** *Curr Issues Mol Biol* 2001, **3**:67-70.
24. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: **Specific human cellular immunity to bcr-abl oncogene-derived peptides.** *Blood* 1996, **87**:3587-3592.
25. Shi M, Qian S, Chen WW, Zhang H, Zhang B, Tang ZR, Zhang Z, Wang FS: **Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.** *Clin Exp Immunol* 2007, **147**:277-286.
26. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C: **Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.** *J Exp Med* 1991, **174**:1565-1570.

doi:10.1186/1743-422X-7-370

Cite this article as: Wu *et al.*: Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy. *Virology Journal* 2010 **7**:370.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

